2024.06.03 MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 GlioblastomaMN-166clinical trials
2024.04.02 MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) GlioblastomaMN-166
2023.11.19 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166clinical trials
2023.08.17 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166
2023.02.20 MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics GlioblastomaMN-166
2023.01.12 MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma GlioblastomaMN-166clinical trials
2022.09.14 MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlioblastomaMN-166
2021.11.22 MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166academic conference
2021.11.04 MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology GlioblastomaMN-166academic conference
2020.06.26 MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology GlioblastomaMN-166treatise
2020.04.21 MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlioblastomaMN-166patents
2019.01.09 再発性グリオブラストーマ（神経膠芽腫（GBM））を適応とするMN-166（イブジラスト）とTMZ（テモゾロミド）の併用療法の患者登録開始のおしらせ GlioblastomaMN-166clinical trials
2017.06.06 米国臨床腫瘍学会2017年次総会におけるMN-166 のグリオブラストーマ（神経膠芽腫）動物モデルスタディに関する学会発表要旨のお知らせ GlioblastomaMN-166academic conference
2017.05.09 第5回世界脳腫瘍学会連合総会におけるMN-166のグリオブラストーマ（神経膠芽腫）を適応とするスタディに関する演題発表見送りのお知らせ GlioblastomaMN-166academic conference
2017.04.10 American Society of Clinical Oncology (米国臨床腫瘍学会（ASCO)）2017年次総会におけるMN-166 のグリオブラストーマ（神経膠芽腫）動物モデルスタディに関する学会発表のお知らせ GlioblastomaMN-166academic conference
2017.02.28 第5回世界脳腫瘍学会連合総会におけるMN-166のグリオブラストーマ（神経膠芽腫）を適応とするスタディに関するアブストラクト発表採択のお知らせ GlioblastomaMN-166academic conference
0202.11.22 第26回 米国神経腫瘍学会議におけるMN-166（イブジラスト）のグリオブラストーマに関する最新データ発表の詳細に関するお知らせ GlioblastomaMN-166academic conference
